Intravitreal ranibizumab and bevacizumab therapy for choroidal neovascularization in age-related macular degeneration with extensive pre-existing geographic atrophy

Avaliação da resposta da injeção intravitrea de ranibizumab e bevacizumab em pacientes com neovascularização de coroide da degeneração macular relacionada à idade com atrofia geográfica extensa pré-existentel

Miguel Hage Amaro1, Aaron Brock Roller2

ABSTRACT

Purpose: To report the response of choroidal neovascularization to intravitreal ranibizumab or bevacizumab treatment in the setting of age-related macular degeneration with extensive pre-existing geographic atrophy of the retinal pigment epithelium.

Methods: This is a retrospective case series of 11 eyes in ten consecutive patients retrieved from a photographic database. The patients were treated with ranibizumab or bevacizumab for neovascular age-related macular degeneration with pre-existing geographic atrophy. Patients were included if they had geographic atrophy at or adjacent to the foveal center of at least 1 disc area in size that was present before the development of choroidal neovascularization. The best corrected visual acuity and optical coherence tomography analysis of the central macular thickness were recorded for each visit. Serial injections of ranibizumab or bevacizumab were administered until there was complete resolution of subretinal fluid on optical coherence tomography data. Over the entire follow-up period were analyzed for overall visual and optical coherence tomography changes.

Results: The patients received an average of 7 ± 3 intravitreal injections over the treatment period. Seven of 11 eyes had reduced retinal thickening on optical coherence tomography. On average, the central macular thickness was reduced by 72 ± 115 µm. Six of these 7 eyes had improvement of one or more lines of vision and one had no change. The average acuity change for all patients was -0.04 ± 0.46 logMAR units, which corresponded to a gain of 0.2 ± 4.4 lines of Snellen acuity. The treatment resulted in a good anatomic response with resolution of the subretinal fluid and overall stable visual acuity.

Conclusions: The results of this case series suggest that the use of an intravitreal anti-vascular endothelial growth factor (VEGF) agent (ranibizumab or bevacizumab) for choroidal neovascularization in age-related macular degeneration with pre-existing geographic atrophy is effective. Our results are not as striking as published for choroidal neovascularization in age-related macular degeneration with extensive geographic atrophy. Patients were included if they had geographic atrophy at or adjacent to the foveal center of at least 1 disc area in size that was present before the development of choroidal neovascularization.

Keywords: Macular degeneration; Geographic atrophy; Retinal pigment epithelium, Choroidal neovascularization, Antibodies, monoclonal/therapeutic use, Retina, Antibodies, monoclonal, humanized; Tomography, optical coherence

RESUMO

Objetivo: Avaliação dos resultados da injeção intravitrea de ranibizumab e bevacizu­­mab em pacientes com neovascularização de coroide da degeneração macular relacionada à idade com aтроfia geográfica extensa pré-existentel. 

Métodos: Este é um estudo retrospectivo de 10 pacientes, 11 olhos com neovasculari­zação de coroide da degeneração macular relacionada à idade, com aтроfia geográf­­ica extensa, pré-existentel. Os pacientes incluídos apresentaram aтроfia geográfica, envolvendo a fóvea ou adjacência, antes do desenvolvimento da neovascularização de coroide. A melhor correção visual e o exame de tomografia de coerência óptica com análise da espessura macular foram registrados em cada visita. As injeções de ranibizumab e bevacizumab intravitrea foram feitas até a resolução do líquido sub­retiniano pela tomografia de coerência óptica e clinicamente. Todos os pacientes tinham seguimento de 6 meses do diagnóstico a 2 anos, com média de 16 meses.

Resultados: Onze olhos de 10 pacientes incluídos receberam uma média de 7 ± 3 injeções intravitreas de ranibizumab e bevacizumab, sendo que 7 apresentaram redu­­ção do espessamento macular pelo tomograma de coerência óptica. A média do resultado do tratamento em logMAR era -0.04 ± 0.46 correlacionando um ganho de visão na tabela de Snellen entre 0.2 ± 4.4 linhas de visão.

Conclusões: Estes resultados sugerem que o uso do ranibizumab e bevacizumab intra­vitrea para neovascularização de coroide da degeneração macular relacionada à idade em extensa aтроfia geográfica pré-existente é eficaz. Há, entretanto dificuldades na avalia­ção da acuidade visual destes pacientes em virtude da extensa aтроfia geográfica que apresentavam e sobre esta ainda a neovascularização de coroide, se comparados a casos em que a neovascularização de coroide não ocorre em aтроfia geográfica pré-existentel.

Descritores: Degeneração macular, Aтроfia geográfica, Epitélio pigmentado da retina, Neovascularização de coroide, Antiboides monoclonais, Tomografia de coerência óptica.
INTRODUCTION

Geographic atrophy (GA) of the retinal pigment epithelium is a form of advanced age-related macular degeneration (AMD) that tends to progress slowly into the center of the macula and cause vision loss. It is defined in the Age-Related Eye Disease Study (AREDS) as a well-defined patch with sharp borders, usually more or less circular shape, and depigmentation of the retinal pigment epithelium (RPE) with exposure of underlying large choroidal blood vessels (1, 2). GA associated with age-related macular degeneration (AMD) is estimated to affect nearly 1% of the US population, with this prevalence expected to increase by 50% by the year 2020 (3).

Histopathological sections of GA show thinning or absence of the RPE, closure of the choriocapillaris, and degeneration of the overlying photoreceptors. The site of the initial appearance of GA is initially occupied by drusen, which are large (>125 μm in diameter) in 96% of cases (4-6). The drusen are usually confluent, with at least two in contact, and sometimes extensive enough to form plaques of drusenoid material. In addition, the GA is nearly always preceded by the appearance of hyperpigmentation around or overlying drusen, followed by regression of the drusen and the appearance of hypopigmentation, sometimes accompanied by refractile deposits. Research has shown that the strongest predictor of the subsequent spread of GA is growth in the previous 2 years (7, 8). Increased fundus autofluorescence outside atrophic patches of GA may also be an important predictor of subsequent progression (9).

Both GA and choroidal neovascularization (CNV) are advanced forms of age-related macular degeneration (2,10). Although pigmentary abnormalities of the RPE and drusen are precursors of neovascularization and GA, the pathophysiologic relationship between these two forms of advanced AMD is unclear. Both are commonly seen simultaneously, and the coexistence of GA and CNV has been proven histopathologically (43,11).

Many studies have shown that the monoclonal antibodies to vascular endothelial growth factor (VEGF), ranibizumab and bevacizumab, improve the visual acuity in patients with AMD and subfoveal CNV (12-16). In the MARINA and ANCHOR trials with ranibizumab, 94.6% and 96.4% of the patients avoided a 15-letter acuity decrease, respectively. Moreover, 34% and 43% of patients gained at least 15 letters of acuity, respectively. The final mean visual acuity improved by 7.2 and 11.3 letters in the MARINA and ANCHOR trials, respectively (12,14). Treatment of CNV with off-label use of the anti-VEGF agent bevacizumab has been shown to be equally effective (16). The more recently introduced anti-VEGF agent aflibercept is also effective in the treatment of CNV, with comparative studies pending (17).

The utility of anti-VEGF intravitreal therapy in the treatment of CNV associated with AMD is well established. The aim of this study is to investigate the role of ranibizumab or bevacizumab intravitreal monotherapy in the treatment of CNV from AMD in eyes with extensive pre-existing GA.

METHODS

This is a retrospective case series study from a photographic database center of 11 eyes in 10 consecutive patients under active treatment with ranibizumab monotherapy for neovascular AMD in the setting of preexisting geographic atrophy. Patients were included if they had an area of GA at or adjacent to the foveal center that was at least 1 disc area in size that was present before or at the time of the development of CNV. Patients were excluded if they had any prior history of or prior treatment for CNV in the study eye. Baseline color fundus photography and fluorescein angiography was performed in all patients. The best corrected Snellen visual acuity and Heidelberg spectral-domain optical coherence tomography (OCT) were obtained at all visits.
Ranibizumab or bevacizumab were injected intravitreally every 4-6 weeks until there was resolution of the subretinal or intraretinal fluid by OCT (Figure 1), or therapy was continued in the case of persistent fluid. After resolution of fluid, a treat-and-extend approach was taken. Data on the overall visual and OCT changes over the entire available follow-up period for each patient were analyzed.

**RESULTS**

The study included 11 eyes from 10 patients. Four eyes were treated with ranibizumab monotherapy and seven eyes with bevacizumab monotherapy. The data for the ranibizumab and bevacizumab treated eyes were considered together for the purpose of this study given the small sample numbers. All patients were followed for at least 6 months (mean 20 months) and up to 3 years after diagnosis. The patients received an average of 7 ± 3 intravitreal injections over the treatment period. Seven eyes had reduced retinal thickening on OCT. On average, the central macular thickness was reduced by 72 ± 115 µm. Six eyes had an improvement of one or more lines of Snellen acuity, three eyes lost three or fewer lines, one eye lost three lines, one eye had dramatic vision loss with hand motions due to macular hemorrhage and one eye had no change in vision (Figure 1). In the eyes with mild vision loss, there was visible expansion of GA over the follow-up period. The CNV developed at the edge of the GA or in spared areas of retinal pigment epithelium within the GA in all but one eye. The average treatment outcome for all patients was -0.04 ± 0.46 logMAR units, which corresponded to a gain of 0.2 ± 4.4 lines of Snellen acuity.

**DISCUSSION**

Choroidal neovascularization and GA are advanced forms of AMD as defined by the AREDS study(12). When CNV develops in eyes with GA, it can cause both an abrupt drop in visual acuity and progression to central vision loss(13). The AREDS data indicate that about one-third of the participants had central GA at the time when GA was first identified. There was a median time to progression from non-central GA to central GA of 2 years. Visual acuity is often decreased before the development of central GA; for those with central GA to central GA of 2 years. Visual acuity is often decreased before the development of central GA; for those with central GA who do not develop CNV, vision is expected to decline an additional 22 letters on average during the next 5 years. Eyes that developed subsequent CNV have an even worse prognosis(13).

CNV in eyes with GA is typically noted to develop at the edge of GA lesions or in new areas previously uninvolved by GA. In a case report on a patient with GA with histopathological correlation in whom the existence of CNV was not initially suspected and a fluorescein angiogram had not revealed CNV, the researchers noted that CNV developed in one eye with GA in areas of residual choriocapillaris and pigment epithelium, while no CNV developed in the fellow eye with GA despite breaks in Bruch’s membrane. This was presumably because the breaks occurred in areas of GA, without residual choriocapillaris and RPE(14). This finding is similar to the recent study by Sunness et al, in which no CNV was noted to develop within areas of GA(15). Our case series also mirrors this finding (Figure 1).

The MARINA and ANCHOR studies proved the efficacy of anti-VEGF therapy with ranibizumab in the treatment of subfoveal CNV(11,12). The CATT study confirmed these results and demonstrated the equivalent efficacy of ranibizumab and bevacizumab(16). In our study of ranibizumab or bevacizumab treatment for CNV in AMD with pre-existing GA, 63% of eyes had improvement of one or more lines of vision, with an average gain of 0.2 lines. In comparison to the Macular Photocoagulation Study, with only 57% of patients with extrafoveal CNV and 26% of patients with juxtapfoveal CNV demonstrating stable or improved vision, our patients had improved outcomes as well(18-20). Given that our patients tended to have poorer vision and central vision loss at baseline due to pre-existing atrophy, our results compare favorably to the other ranibizumab and bevacizumab studies, with disappearance of the subretinal fluid and overall stable visual acuity. Therefore GA, of itself, should not be a contraindication to anti-VEGF treatment for eyes with CNV.

**CONCLUSION**

This small case series demonstrates that the use of the intravitreal anti-VEGF agents ranibizumab and bevacizumab for CNV in AMD with significant preexisting GA was largely effective for the patients in our series. Our results are not as striking as the results of large-scale trials of anti-VEGF therapy for subfoveal CNV, presumably due to the limitation of improvement of visual acuity over baseline caused by the underlying GA. Our study is limited by a very small sample size, and a larger prospective study with longer follow-up is needed to confirm our results.

<table>
<thead>
<tr>
<th>Eye</th>
<th>Agent</th>
<th>Initial acuity (Snellen)</th>
<th>Number of injections</th>
<th>Follow-up (months)</th>
<th>Final acuity (Snellen)</th>
<th>Total change in acuity lines</th>
<th>Change in OCT from baseline (µm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Bevacizumab</td>
<td>20/100</td>
<td>3</td>
<td>6</td>
<td>20/70</td>
<td>+2</td>
<td>-167</td>
</tr>
<tr>
<td>2</td>
<td>Bevacizumab</td>
<td>20/160</td>
<td>6</td>
<td>24</td>
<td>20/200</td>
<td>-1</td>
<td>-215</td>
</tr>
<tr>
<td>3</td>
<td>Ranibizumab</td>
<td>20/40</td>
<td>10</td>
<td>30</td>
<td>20/300</td>
<td>-9</td>
<td>-50</td>
</tr>
<tr>
<td>4</td>
<td>Ranibizumab</td>
<td>20/250</td>
<td>5</td>
<td>24</td>
<td>20/70</td>
<td>+6</td>
<td>-91</td>
</tr>
<tr>
<td>5</td>
<td>Bevacizumab</td>
<td>20/60</td>
<td>3</td>
<td>16</td>
<td>20/100</td>
<td>-3</td>
<td>15</td>
</tr>
<tr>
<td>6</td>
<td>Bevacizumab</td>
<td>20/125</td>
<td>3</td>
<td>16</td>
<td>20/80</td>
<td>+2</td>
<td>-201</td>
</tr>
<tr>
<td>7</td>
<td>Ranibizumab</td>
<td>20/40</td>
<td>11</td>
<td>30</td>
<td>20/40</td>
<td>0</td>
<td>52</td>
</tr>
<tr>
<td>8</td>
<td>Bevacizumab</td>
<td>20/400</td>
<td>10</td>
<td>12</td>
<td>20/50</td>
<td>+7</td>
<td>-227</td>
</tr>
<tr>
<td>9</td>
<td>Bevacizumab</td>
<td>20/600</td>
<td>6</td>
<td>8</td>
<td>20/800</td>
<td>-1</td>
<td>12</td>
</tr>
<tr>
<td>10</td>
<td>Bevacizumab</td>
<td>20/50</td>
<td>12</td>
<td>21</td>
<td>20/70</td>
<td>-2</td>
<td>-16</td>
</tr>
<tr>
<td>11</td>
<td>Ranibizumab</td>
<td>20/60</td>
<td>5</td>
<td>36</td>
<td>20/50</td>
<td>+1</td>
<td>93</td>
</tr>
</tbody>
</table>

Average: 7 ± 3 20 ± 10 +0.2 ± 4.4 -72 ± 115
ACKNOWLEDGEMENTS
We thank Dr. James C. Folk, the Judith (Gardner) and Donald H. Beisner, M.D. Professor of Vitreoretinal Diseases and Surgery at the University of Iowa, Iowa City, Iowa USA for his generous help with the design and completion of this study.

REFERENCES